LifeSci Venture Partners focuses on investing in clinical-stage companies within the biotech, life sciences, medicine, technology, and healthcare sectors across the United States. They seek transformational business models with proof-of-concept, aiming for companies that plan to go public within 12-18 months.
50% of their portfolio is in Healthcare. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-b (50% of deals). Average disclosed round size is $64.8M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Veradermics | Series C | $150M | Oct 2025 |
 Brainomix | Series C | $18M | Mar 2025 |
 Averto Medical Inc | Series A | $30.5M | May 2024 |
 Beta Bionics, Inc. | Series C | $57M | Feb 2022 |
 Antios Therapeutics | Series B | $75M | Nov 2021 |
 Science 37 | Series B | $40M | Aug 2020 |
 Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
| Beta Bionics, Inc. | Series B | $63M | Jan 2019 |
Top Co-Investors
Perceptive Advisors2 shared
RTW Investments2 shared
Soleus Capital2 shared
ArrowMark Partners2 shared
Parkwalk Advisors1 shared
Boehringer Ingelheim Venture Fund1 shared
Hostplus1 shared
Cormorant Asset Management1 shared
Viking Global Investors1 shared
Franklin Templeton1 shared
Rock Springs Capital1 shared
Surveyor Capital1 shared
Logos Capital1 shared
Janus Henderson Investors1 shared
Sofinnova Partners1 shared
Avidity Partners1 shared
SR One1 shared
Viking Global1 shared
Marshall Wace1 shared
Last updated: 16 April 2026